Borimas Hanboonkunupakarn, Mavuto Mukaka, Podjanee Jittamala, Kittiyod Poovorawan, Pongphaya Pongsuwan, Lisa Stockdale, Samuel Provstgaard-Morys, Kesinee Chotivanich, Joel Tarning, Richard M Hoglund, Natenapa Chimjinda, Katie Ewer, Fernando Ramos-Lopez, Nicholas P J Day, Arjen M Dondorp, Adrian V Hill, Nicholas J White, Lorenz von Seidlein, Sasithon Pukrittayakamee
{"title":"在泰国成年人中开展的疟疾疫苗 R21/Matrix-M™ 添加或不添加抗疟药物的随机试验。","authors":"Borimas Hanboonkunupakarn, Mavuto Mukaka, Podjanee Jittamala, Kittiyod Poovorawan, Pongphaya Pongsuwan, Lisa Stockdale, Samuel Provstgaard-Morys, Kesinee Chotivanich, Joel Tarning, Richard M Hoglund, Natenapa Chimjinda, Katie Ewer, Fernando Ramos-Lopez, Nicholas P J Day, Arjen M Dondorp, Adrian V Hill, Nicholas J White, Lorenz von Seidlein, Sasithon Pukrittayakamee","doi":"10.1038/s41541-024-00920-1","DOIUrl":null,"url":null,"abstract":"<p><p>In preparation for mass vaccinations with R21/Matrix-M™ combined with mass administrations of dihydroartemisinin, piperaquine, and a single low dose primaquine we assessed the tolerability, safety, and potential interactions of this combination affecting immunogenicity or pharmacokinetics. 120 healthy Thai volunteers were randomised to receive either antimalarials combined with vaccinations (n = 50), vaccinations alone (n = 50), or antimalarials only (n = 20). Three rounds of vaccines and antimalarials were administered one month apart. The vaccine was well tolerated alone and in combination with the antimalarials. None of the participants failed completion of the 3-dose vaccine course. There was no significant difference in the vaccine immunogenicity or in the pharmacokinetics of piperaquine given individually or in combination. This study supports proceeding to a large trial of mass vaccinations with R21/Matrix-M™ combined with mass antimalarial administration in Bangladesh.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227592/pdf/","citationCount":"0","resultStr":"{\"title\":\"A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.\",\"authors\":\"Borimas Hanboonkunupakarn, Mavuto Mukaka, Podjanee Jittamala, Kittiyod Poovorawan, Pongphaya Pongsuwan, Lisa Stockdale, Samuel Provstgaard-Morys, Kesinee Chotivanich, Joel Tarning, Richard M Hoglund, Natenapa Chimjinda, Katie Ewer, Fernando Ramos-Lopez, Nicholas P J Day, Arjen M Dondorp, Adrian V Hill, Nicholas J White, Lorenz von Seidlein, Sasithon Pukrittayakamee\",\"doi\":\"10.1038/s41541-024-00920-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In preparation for mass vaccinations with R21/Matrix-M™ combined with mass administrations of dihydroartemisinin, piperaquine, and a single low dose primaquine we assessed the tolerability, safety, and potential interactions of this combination affecting immunogenicity or pharmacokinetics. 120 healthy Thai volunteers were randomised to receive either antimalarials combined with vaccinations (n = 50), vaccinations alone (n = 50), or antimalarials only (n = 20). Three rounds of vaccines and antimalarials were administered one month apart. The vaccine was well tolerated alone and in combination with the antimalarials. None of the participants failed completion of the 3-dose vaccine course. There was no significant difference in the vaccine immunogenicity or in the pharmacokinetics of piperaquine given individually or in combination. This study supports proceeding to a large trial of mass vaccinations with R21/Matrix-M™ combined with mass antimalarial administration in Bangladesh.</p>\",\"PeriodicalId\":19335,\"journal\":{\"name\":\"NPJ Vaccines\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2024-07-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227592/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41541-024-00920-1\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-024-00920-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.
In preparation for mass vaccinations with R21/Matrix-M™ combined with mass administrations of dihydroartemisinin, piperaquine, and a single low dose primaquine we assessed the tolerability, safety, and potential interactions of this combination affecting immunogenicity or pharmacokinetics. 120 healthy Thai volunteers were randomised to receive either antimalarials combined with vaccinations (n = 50), vaccinations alone (n = 50), or antimalarials only (n = 20). Three rounds of vaccines and antimalarials were administered one month apart. The vaccine was well tolerated alone and in combination with the antimalarials. None of the participants failed completion of the 3-dose vaccine course. There was no significant difference in the vaccine immunogenicity or in the pharmacokinetics of piperaquine given individually or in combination. This study supports proceeding to a large trial of mass vaccinations with R21/Matrix-M™ combined with mass antimalarial administration in Bangladesh.
NPJ VaccinesImmunology and Microbiology-Immunology
CiteScore
11.90
自引率
4.30%
发文量
146
审稿时长
11 weeks
期刊介绍:
Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.